Future Forum

Begin

End

Location

Organiser

Gene therapies, personalised tumour vaccines, antibody-guided therapies: major scientific advances in biotechnology are currently being made in the treatment of patients. These advances enable therapeutic approaches that were previously unimaginable.

The potential and impact of such biotech innovations are the focus of the Federal Ministry of Health's Future Forum, in which the Federal Minister of Health will actively participate. High-level representatives from healthcare, health policy, patient organisations, academia, research companies, and regulatory authorities will come together during the Future Forum for an interdisciplinary dialogue.

As the Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich-Institut is an important actor for these innovative medicines at the European and national levels because it supports the regulatory development and authorisation of these medicinal product groups. From scientific advice to authorisation, the Institute works to ensure that progress is possible for targeted and personalised therapies such as individualised tumour vaccines and gene therapies for the treatment of serious and previously incurable diseases. The Paul-Ehrlich-Institut continues to be intensively involved post-authorisation in monitoring these medicinal product groups, especially with regard to pharmacovigilance.

The first part of the forum, titled "Biotech Innovations – Research Opportunities" will be moderated by Dr Martina Schüssler-Lenz from the Paul-Ehrlich-Institut, former long-standing chair of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA).

In the second part of the forum, Dr Mathias Renner, a section head within the Haematology, Cell and Gene Therapy Division at the Paul-Ehrlich-Institut, will inform participants about the current "Trends in the Development of Innovative Biotechnological and Gene Therapeutic Medicinal Products".

Participation

In-person participation is by invitation only. A livestream is planned.